SASCIA (GBG 102) – successful start of the study!
12.11.2020
First patient included.
The phase III postneoadjuvant study with the antibody-drug conjugate sacituzumab govitecan in women with early HER2-negative breast cancer and a high risk of relapse started successfully in November 2020.
We congratulate the gynecological clinic of the Caritasklinik St. Theresia, Saarbrücken for recruiting the first patient.
News
28.02.2021 February 2021: Signatures of mutational processes and response to neoadjuvant chemotherapy in breast cancer
A translational research project investigating genomic patterns of mutational signatures in breast cancer patients from GeparSepto trial has been published in Annals of Oncology.
Mehr ...26.02.2021 January 2021: Final results of the MALE study
We are delighted to inform you that final results of the first randomized phase II MALE trial have been published in JAMA Oncology.
Mehr ...17.02.2021 OlympiA trial crossed superiority boundary for invasive disease-free survival
IDMC has concluded that OlympiA trial crossed superiority boundary for invasive disease-free survival vs. placebo at planned interim analysis. OlympiA Phase III trial of Lynparza in the adjuvant treatment of BRCA-mutated HER2-negative high-risk early breast cancer will be analysed and reported early.
Mehr ...17.02.2021 REGISTRATION OPEN: GBG Annual Meeting 2021
The GBG Annual Meeting will be held february 24th to 26th 2021 as a virtual conference.
Mehr ...04.02.2021 December 2020: Effect of germline BRCA1/2 mutations on haematological toxicities after neoadjuvant chemotherapy.
A retrospective analysis investigating the effect of germline BRCA1/2 mutations on severe haematological toxicities in TNBC patients treated with chemotherapy has been published in European Journal of Cancer.
Mehr ...